Mesothelin-targeted CAR-T cell therapy for solid tumors.
Loading...
Embargo End Date
ICR Authors
Authors
Klampatsa, A
Dimou, V
Albelda, SM
Dimou, V
Albelda, SM
Document Type
Journal Article
Date
2021-04-03
Date Accepted
2020-10-26
Abstract
Introduction: Mesothelin (MSLN) is a tumor differentiation antigen normally restricted to the body's mesothelial surfaces, but significantly overexpressed in a broad range of solid tumors. For this reason, MSLN has emerged as an important target for the development of novel immunotherapies. This review focuses on anti-MSLN chimeric antigen receptor (CAR) T cell immunotherapy approaches.Areas covered: A brief overview of MSLN as a therapeutic target and existing anti-MSLN antibody-based drugs and vaccines is provided. A detailed account of anti-MSLN CAR-T cell approaches utilized in preclinical models is presented. Finally, a comprehensive summary of currently ongoing and completed anti-MSLN CAR-T cell clinical trials is discussed.Expert opinion: Initial trials using anti-MSLN CAR-T cells have been safe, but efficacy has been limited. Employing regional routes of delivery, introducing novel modifications leading to enhanced tumor infiltration and persistence, and improved safety profiles and combining anti-MSLN CAR-T cells with standard therapies, could render them more efficacious in the treatment of solid malignancies.
Citation
Expert opinion on biological therapy, 2020, pp. 1 - 14
Source Title
Publisher
TAYLOR & FRANCIS LTD
ISSN
1471-2598
eISSN
1744-7682
Collections
Research Team
Thoracic Oncology Immunotherapy Group (TOIG)
Thoracic Oncology Immunotherapy Group (TOIG)
Thoracic Oncology Immunotherapy Group (TOIG)